文献速递前列腺癌

帕德利泊芬血管靶向光动力治疗后根治性前列腺切除术的可行性与早期及中期结果

Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
PubMed 文献 · J Urol · 2019-01-01

回顾性纳入欧洲14个中心2008年10月至2017年3月共45例因血管靶向光动力治疗后复发前列腺癌行挽救性根治性前列腺切除术的患者,其中42例完成手术。主要终点为并发症和技术困难,结果显示手术对多数术者可行且安全。

要点

  • 挽救性根治性前列腺切除术后并发症发生率为12%,包括Clavien I、II、IIIB级。
  • 术者评估手术容易者占69%,困难者占31%。
  • 术后6至12个月37例(88%)患者PSA不可测。

核心结论

  • 血管靶向光动力治疗后行挽救性根治性前列腺切除术对多数术者可行且安全。

研究设计与样本

  • 回顾性研究纳入欧洲14个中心2008年10月至2017年3月共45例患者,其中42例行根治性前列腺切除术(机器人辅助16例、腹腔镜6例、开放20例)。

主要发现

  • 中位手术时间180分钟(IQR 150-223),中位失血量200 ml(IQR 155-363)。
  • 术者评估手术容易29例(69%)、困难13例(31%),神经保留可行14例(33%)。
  • 术后并发症5例(12%),包括Clavien I 2例、Clavien II 2例、Clavien IIIB 1例。
  • 术后病理pT3 13例(31%)、pT2c 21例(50%),手术切缘阳性13例(31%)。
  • 术后6至12个月37例(88%)PSA不可测,9例接受辅助放疗;中位随访23个月(IQR 12-36)时4例最终PSA大于0.2 ng/ml。

临床怎么用

  • 对于血管靶向光动力治疗后复发的前列腺癌患者,挽救性根治性前列腺切除术是可行选择,但需注意部分病例手术困难及切缘阳性风险。

局限性

  • 回顾性研究设计,样本量有限(45例纳入,42例手术),随访时间较短(中位23个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vascular targeted photodynamic therapy with TOOKAD® is a new therapeutic option for localized prostate cancer management. The objectives of this study were to assess the feasibility of radical prostatectomy after vascular targeted photodynamic therapy and describe functional and oncologic outcomes. MATERIALS AND METHODS: We retrospectively included in study 45 patients who underwent salvage radical prostatectomy after vascular targeted photodynamic therapy for recurrent prostate cancer at a total of 14 surgical centers in Europe between October 2008 and March 2017. Of the 42 radical prostatectomies performed 16 were robot-assisted, 6 were laparoscopic and 20 were open surgery. Primary end points were morbidity and technical difficulties. Secondary end points were early and intermediate postoperative functional and oncologic outcomes. RESULTS: Median operative time was 180 minutes (IQR 150-223). Median blood loss was 200 ml (IQR 155-363). According to the surgeons the surgery was easy in 29 patients (69%) and difficult in 13 (31%). Nerve sparing was feasible in 14 patients (33%). Five postoperative complications (12%) were found, including 2 Clavien I, 2 Clavien II and 1 Clavien IIIB complications. Of the cases 13 (31%) were pT3 and 21 (50%) were pT2c. Surgical margins were positive in 13 patients (31%). Prostate specific antigen was undetectable at 6 to 12 months in 37 patients (88%). Nine patients underwent complementary radiotherapy. Four patients had final prostate specific antigen greater than 0.2 ng/ml at a median followup of 23 months (IQR 12-36). At 1 year 27 patients (64%) were completely continent (no pads) and 10 (24%) had low incontinence (1 pad). Four patients (11%) recovered potency without treatment and 23 (64%) recovered potency with appropriate treatment. CONCLUSIONS: Salvage radical prostatectomy after vascular targeted photodynamic therapy treatment was feasible and safe without difficulty for most of the surgeons.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pierrard V, Lebdai S, Kleinclauss F, et al. Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. J Urol. 2019. PMID: 30248343. doi:10.1016/j.juro.2018.08.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。